Stocktoria
Organogenesis Holdings Inc. ORGO
Organogenesis Holdings Inc. (ORGO) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $564.2M at a 6.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.438 |
| Retained earnings / assets | -0.005 |
| EBIT / assets | 0.075 |
| Equity / liabilities | 1.821 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ORGO | Organogenesis Holdings Inc. | 3/9 | 5.27 | 8.4 | +17% |
| HCM | HUTCHMED (China) Ltd | 4/9 | 6.45 | 31.3 | -13% |
| CPRX | CATALYST PHARMACEUTICALS, INC. | 4/9 | 14.1 | 18 | +19.8% |
| INSM | INSMED Inc | 3/9 | -7.47 | — | +66.7% |
| OPK | OPKO HEALTH, INC. | 4/9 | -0.79 | — | -14.9% |
| MIRM | Mirum Pharmaceuticals, Inc. | 4/9 | 0.54 | — | +54.7% |
| TGTX | TG THERAPEUTICS, INC. | 4/9 | 2.04 | 19.1 | +87.3% |
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
FAQ
Is ORGO financially healthy?
Organogenesis Holdings Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ORGO pay a dividend?
No, Organogenesis Holdings Inc. does not currently pay a dividend.
How profitable is ORGO?
In FY2025, Organogenesis Holdings Inc. had a net margin of 6.6% and a return on equity of 12.3%.
Is ORGO overvalued or undervalued?
Organogenesis Holdings Inc. trades at about 12.1× trailing earnings — below its 10-year norm (10-year range 11.0×–82.5×, median 26.7×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ORGO?
The average Wall-Street price target for Organogenesis Holdings Inc. is $3.00, about 65.7% above the recent price, from 1 analysts.
Is ORGO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Organogenesis Holdings Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone, a P/E of about 8.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.